Can Cannabis Be Used to Manage PTSD Symptoms?

Cannabis is not an established treatment for post-traumatic stress disorder (PTSD) overall. Some people report temporary relief, and certain cannabinoid medicines have shown benefits for nightmares, but these findings need to be considered alongside negative trials and safety concerns. The product studied, the symptom measured, and the length of follow-up all matter.

PTSD can develop after trauma and involve intrusive memories, avoidance, persistent changes in mood or thinking, and feeling constantly on guard. It can disrupt sleep, relationships, and daily activities. Effective treatment is available, including for people whose first treatment did not provide enough relief.

What Current Treatment Guidance Says

The 2023 VA/DoD guideline strongly recommends against cannabis or cannabis derivatives as PTSD treatment, citing insufficient efficacy evidence and known risks. That recommendation predates the 2026 nightmare trial discussed below. A new positive study warrants attention, but does not automatically change a published guideline or establish an appropriate treatment for every person with PTSD.

There is no established retail cannabis dose or THC-to-CBD ratio for treating PTSD. THC is intoxicating; CBD does not produce the same high, but that difference does not establish PTSD benefit. Results for prescription cannabinoids cannot be assumed to apply to flower, gummies, or CBD oils.

Smoked Cannabis Did Not Outperform Placebo

In a 2021 randomized trial, 80 military veterans initially received one of three smoked cannabis preparations or placebo for three weeks. The preparations emphasized THC, CBD, or a combination of both. Symptoms improved across groups, including placebo, but no active preparation significantly outperformed placebo on the main PTSD severity outcome.

This was a short, preliminary study, so it cannot resolve every question about every formulation. It does show why improvement after starting cannabis is not enough to prove that cannabis caused the improvement.

Nightmares: Promising Findings With Important Limits

An early nabilone crossover trial, published online in 2014 and in a 2015 journal issue, found fewer or less intense nightmares than placebo in a very small sample of Canadian military personnel. Only ten participants were included in its main analysis. The drug was nabilone, and the journal was Psychoneuroendocrinology; this was not a large trial of plant cannabis.

A larger August 2026 dronabinol trial randomized 171 adults with PTSD and recurrent nightmares to a prescribed THC preparation or placebo for ten weeks. Dronabinol produced a greater reduction in nightmare frequency and intensity on the study scale, with a between-group difference of 1.50 points favoring treatment.

Safety deserves equal attention. Adverse events occurred in 89.7% of dronabinol recipients and 77.1% of placebo recipients; serious adverse events occurred in seven people receiving dronabinol and none receiving placebo. Those counts alone do not establish that the medicine caused every event. The authors called for further evaluation of long-term efficacy and safety.

This provides evidence for a specific medicine and symptom under trial conditions. It does not show that smoking cannabis treats PTSD, that all cannabinoids are interchangeable, or that long-term self-medication is safe.

Risks, Dependence, and Trauma Treatment

The VA describes risks including cannabis use disorder, cognitive impairment, and adverse mental health effects. Increasing use, difficulty cutting down, or continuing despite problems are reasons to discuss support. Withdrawal can complicate sleep and anxiety, so a clinician can help plan and monitor changes.

People who use cannabis can still benefit from trauma-focused treatment. The VA recommends treating PTSD and substance use problems together rather than overlooking either condition. Disclosing cannabis use should help the care team understand symptoms and treatment needs.

A 2026 preliminary study followed 21 people with both PTSD and cannabis use disorder during a supported abstinence program. The 11 who achieved abstinence had larger PTSD symptom improvements than the ten who did not. Because abstinence was not randomly assigned and the sample was small, this does not prove that stopping cannabis caused the difference. It does challenge the assumption that continued cannabis use is necessary for symptom relief.

Better-Supported Options to Discuss

The VA/DoD treatment framework prioritizes trauma-focused therapies such as cognitive processing therapy, prolonged exposure, and eye movement desensitization and reprocessing (EMDR). These approaches address PTSD directly rather than relying only on temporary changes in distress or sleep.

The VA’s medication guide recommends sertraline, paroxetine, or venlafaxine when medication is appropriate. It suggests prazosin specifically for PTSD-associated nightmares, while advising against using it for PTSD overall. Medication selection and monitoring should account for other conditions, side effects, and personal preferences.

Tell the clinician which symptoms remain troublesome, what treatments you have already tried, and what cannabis products or other substances you use. In the United States, someone struggling or having thoughts of suicide can call or text 988 for immediate crisis support.